NICE now recommends Roche's Gazyvaro for CLL

The U.K.'s NICE issued final draft guidance recommending Gazyvaro obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) in combination with chlorambucil as first-line therapy for chronic lymphocytic leukemia (CLL) in patients unsuitable for fludarabine-based therapy.

NICE reversed its preliminary appraisal determination after the pharma agreed to provide Gazyvaro at an undisclosed discount under a patient access scheme. The company also submitted revised cost-effectiveness data that NICE said addressed the committee's concerns. ...